Loading…
MapLight Therapeutics, Inc. is projected to rise to $40.03 by 2027, a +35% move from its current price of $29.55. MPLT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $28.41 | $29.57 | $30.77 | +0.06% |
| May 30 | $27.96 | $29.58 | $31.30 | +0.12% |
| May 31 | $27.62 | $29.60 | $31.72 | +0.18% |
| Jun 1 | $27.35 | $29.62 | $32.08 | +0.23% |
| Jun 2 | $27.11 | $29.64 | $32.40 | +0.29% |
| Jun 3 | $26.89 | $29.65 | $32.70 | +0.35% |
| Jun 4 | $26.70 | $29.67 | $32.98 | +0.41% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $26.70 | $29.67 | $32.98 | +0.41% |
| Week 2 | $25.66 | $29.79 | $34.59 | +0.82% |
| Week 3 | $24.92 | $29.92 | $35.92 | +1.24% |
| Week 4 | $24.32 | $30.04 | $37.10 | +1.65% |
| Week 5 | $23.82 | $30.16 | $38.19 | +2.07% |
| Week 6 | $23.38 | $30.29 | $39.23 | +2.49% |
| Week 7 | $23.00 | $30.41 | $40.21 | +2.91% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on patients with debilitating central nervous system disorders. The company’s product lineup includes ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist for schizophrenia and Alzheimer's disease psychosis; ML-004 for social communication deficits and irritability in autism spectrum disorder; ML-021 for motor deficits in Parkinson’s disease; ML-055 for neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for hyperactivity, impulsivity and agitation-related disorders.
The company also develops a platform that identifies neural circuits causally linked to disease and targets those circuits for therapeutic modulation.
MapLight Therapeutics, Inc. was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. The company was incorporated in 2018 and is based in Redwood City, California. The description places the company in the Healthcare sector.
MapLight Therapeutics, Inc. (MPLT) is currently trading at $28.75 per share and carries a market cap of $1.3B. It is ranked 2330 by market capitalization in the listed universe. The stock shows a wide capital-structure footprint typical of clinical-stage biopharma outfits with execution risk tied to clinical milestones and regulatory approvals.
The price outlook through the 2026–2050 forecast shows meaningful upside from the current level. The 2026 average price is $28.75 with a 0% ROI, followed by substantial upside in subsequent years: 2027 avg $39.08 (ROI 35.9%), 2028 avg $45.37 (57.8%), 2029 avg $45.81 (59.3%), and 2030 avg $68.61 (138.7%). Long-run forecasts extend to 2040 avg $253.39 (781.4% ROI) and 2050 avg $531.90 (1,750.1% ROI), with bullish sentiment indicated across many years.
A major floor 46.9% below — a decisive break under it would weaken the trend.
The nearest floor, 10.3% below — buyers have tended to step in here.
The nearest ceiling, 8.7% above — a clean break opens room to run.
A major ceiling 18.5% above — clearing it would confirm fresh momentum.
Key MPLT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MPLT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $28.97 | Buy | $29.06 | Buy |
| MA 10 | $28.71 | Buy | $28.90 | Buy |
| MA 20 | $29.13 | Buy | $28.67 | Buy |
| MA 50 | $25.95 | Buy | $26.41 | Buy |
| MA 100 | $21.89 | Buy | $23.60 | Buy |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.99 | Neutral |
| Stoch RSI (14) | 69.59 | Neutral |
| CCI (20) | 27.37 | Neutral |
| Williams %R (14) | -26.86 | Info |
| MACD (12,26,9) | -0.22 | Sell |
| ROC (12) | 7.85 | Buy |
| Bollinger %B (20,2) | 0.58 | Neutral |
| Stochastic %K (14) | 73.14 | Neutral |
| TRIX (15) | 0.42 | Buy |
| Awesome (5,34) | -0.01 | Sell |
| Ultimate (7,14,28) | 54.46 | Neutral |
| Momentum (10) | -0.75 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 29.62 | Sell |
| ADX (14) | 15.01 | Neutral |
| ATR (14) | 1.01 | Info |
The 30-day technical picture presents a bullish tilt overall. RSI(14) is 50, and the 50-day simple moving average is $25.53, suggesting the short-term momentum is not overbought. Support sits at $26.31 and resistance at $32.13, framing a range that can guide near-term trading decisions.
The 30-day trading range spans from $21.76 to $37.98, illustrating meaningful volatility within a broad corridor. The current technical posture favors upside potential above the near-term support, with a defined ceiling near the $32.13 resistance level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $15.70 | $29.55 | $44.42 | 0% | Neutral | |
| $28.08 | $40.03 | $61.87 | +35% | Bullish | |
| $30.98 | $47.31 | $78.14 | +60% | Bullish | |
| $29.42 | $47.70 | $82.93 | +61% | Bullish | |
| $40.94 | $70.13 | $127.22 | +137% | Bullish | |
| $53.26 | $96.10 | $180.84 | +225% | Bullish | |
| $55.26 | $104.82 | $203.75 | +255% | Bullish | |
| $61.84 | $123.18 | $246.47 | +317% | Bullish | |
| $59.84 | $125.02 | $256.86 | +323% | Bullish | |
| $60.68 | $132.91 | $279.80 | +350% | Bullish | |
| $118.97 | $264.38 | $608.06 | +795% | Bullish | |
| $245.10 | $544.67 | $1,252.74 | +17.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $15.70 | $29.55 | $35.30 | +0.00% |
| June 2026 | $25.69 | $30.97 | $38.80 | +4.81% |
| July 2026 | $25.37 | $31.17 | $40.16 | +0.64% |
| August 2026 | $24.03 | $29.98 | $39.46 | -3.83% |
| September 2026 | $24.00 | $30.32 | $40.60 | +1.14% |
| October 2026 | $24.80 | $31.69 | $43.09 | +4.51% |
| November 2026 | $24.50 | $31.63 | $43.59 | -0.19% |
| December 2026 | $24.41 | $31.83 | $44.42 | +0.63% |
Click any year to see its month-by-month MPLT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MPLT is projected to trade between $15.70 and $44.42, averaging $29.55 — a potential gain of 0% from today's $29.55. Price action looks broadly range-bound.
MapLight Therapeutics, Inc.'s 2027 outlook centres on $40.03, within a $28.08 to $61.87 range. That is up +35% on the projected 2026 average. That marks a +35% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, MPLT could reach as high as $78.14, with a base case around $47.31 and support toward $30.98 — roughly +60% from $29.55. Momentum favours further upside here.
Expect MPLT to range from $29.42 to $82.93 through 2029. The $47.70 average target implies a +61% move from current prices. That is up +1% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The MPLT price prediction for 2030 points to an average of $70.13 (low $40.94, high $127.22) — a potential gain of +137% on today's $29.55. Momentum favours further upside here.
In 2031, MPLT is projected to trade between $53.26 and $180.84, averaging $96.10 — a potential gain of +225% from today's $29.55. That is up +37% on the projected 2030 average. Buyers look set to stay in control over this stretch.
MapLight Therapeutics, Inc.'s 2032 outlook centres on $104.82, within a $55.26 to $203.75 range. That is up +9% on the projected 2031 average. That marks a +255% change versus current levels. Momentum favours further upside here.
By 2033, MPLT could reach as high as $246.47, with a base case around $123.18 and support toward $61.84 — roughly +317% from $29.55. Buyers look set to stay in control over this stretch.
Expect MPLT to range from $59.84 to $256.86 through 2034. The $125.02 average target implies a +323% move from current prices. That is up +1% on the projected 2033 average. Momentum favours further upside here.
The MPLT price prediction for 2035 points to an average of $132.91 (low $60.68, high $279.80) — a potential gain of +350% on today's $29.55. Buyers look set to stay in control over this stretch.
In 2040, MPLT is projected to trade between $118.97 and $608.06, averaging $264.38 — a potential gain of +795% from today's $29.55. That is up +99% on the projected 2035 average. Momentum favours further upside here.
MapLight Therapeutics, Inc.'s 2050 outlook centres on $544.67, within a $245.10 to $1,252.74 range. That is up +106% on the projected 2040 average. That marks a +17.4x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in MPLT today (≈ 33.840948 MPLT) could be worth
$18,432.09
+$17,432.09 (+1743%) by 2050 · US Dollar
Based on the average projected MPLT price of $544.67 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MPLTwould be worth at today's price.
$1,000 invested in MPLT on Oct 27, 2025 (≈ 54.525627 MPLT) would be worth
$1,611.23
+$611.23 (+61.1%) today · 1.61× · US Dollar
Based on a MPLT entry price of $18.34 vs. today's $29.55.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $27.81 | $1,062.57 | +6.3% |
| 1 month ago | $30.64 | $964.43 | -3.6% |
| 3 months ago | $17.42 | $1,696.33 | +69.6% |
| 6 months ago | $13.63 | $2,168.01 | +116.8% |
| All time ago | $18.34 | $1,611.23 | +61.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MPLT forecast.
Our base-case forecast reaches $59.00 around 2030.
Implied market cap at $59.00: $2.51B
The multi-year forecast presents a clear path of upside potential from the current level. In 2030, the average forecast price is $68.61 with a 138.7% ROI and bullish sentiment. By 2040, the average price is projected at $253.39 with a striking 781.4% ROI, continuing the bullish trajectory.
In 2050, the average forecast price reaches $531.90 with a 1,750.1% ROI, underscoring a long-run uptrend in the model’s view.
These projections imply substantial appreciation from the current price, but they are estimates and carry uncertainty. The forecast expresses a bullish stance across multiple years, yet actual outcomes will depend on clinical milestones, regulatory events, and market dynamics. Investors should regard these figures as guidance rather than guarantees.
Tap a question to reveal the answer.
The forecasted average price for 2030 is $68.61, with a minimum of $38.89 and a maximum of $127.15. The estimated ROI for 2030 is 138.7% and the sentiment is BULLISH.
The forecast shows meaningful upside beyond the current price, with the average price rising to $68.61 by 2030 and higher in 2040 ($253.39) and 2050 ($531.90). The model signals bullish sentiment in the longer term, with several years presenting double- or triple-digit ROI projections, though these are estimates and not guaranteed.
Yes. The forecast shows 2032 with an average price of $102.06 and 2033 with an average price of $120.27, indicating that the asset could surpass $100 in the mid-2030s on average.
Current price is $28.75 per share and the market cap is $1.3B.
The 30-day picture shows bullish sentiment with RSI(14) at 50 and a 50-day SMA of $25.53. Support is at $26.31 and resistance at $32.13, with the 30-day range spanning $21.76 to $37.98 and annualized volatility at 80%.
MapLight Therapeutics, Inc. Community Discussion
0Share your MapLight Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.